|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9731082||FRESENIUS KABI USA||Drug container|| |
(8 years from now)
|US9248229||FRESENIUS KABI USA||Packaging system for oxygen-sensitive drugs|| |
(10 years from now)
Dilaudid is owned by Fresenius Kabi Usa.
Dilaudid contains Hydromorphone Hydrochloride.
Dilaudid has a total of 2 drug patents out of which 0 drug patents have expired.
Dilaudid was authorised for market use on 11 January, 1984.
Dilaudid is available in injectable;injection dosage forms.
The generics of Dilaudid are possible to be released after 12 March, 2034.
Market Authorisation Date: 11 January, 1984
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic